RSS

UCART123

Clinical-stage biopharmaceutical company, Cellectis, has received a notice from the US Food and Drug Administration (FDA) that a clinical hold has been placed on its ongoing Phase I studies evaluating the CAR-T therapy (UCART123) after a fatality. more

News